Effect of stem cell application on Asherman Syndrome, an experimental rat model

Kılıç, Sevtap; Yüksel, Beril; Pınarlı, Ferda Alpaslan; Albayrak, Aynur; Boztok, Başak; Delibaşı, Tuncay

doi:10.1016/j.fertnstert.2013.07.1771

Cited by 10 publications

(15 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings showed that implantation and conception rates in rats with AS treated with BMSCs were comparable to rats with normal uteri. Although there were a number of animal and clinical studies on BMSC treatment for AS, [14][15][16][17][18][19][24][25][26][27][28] the exact mechanisms on how BMSCs regenerate the damaged endometrium remained largely unknown and might involve complex molecular pathways. Further mechanistic studies and clinical trials involving large cohorts are needed to affirm the efficacy of this novel treatment to offer hope to women with this debilitating disease a chance to conceive again.…”

Section: Discussionmentioning

confidence: 99%

Bone Marrow Mesenchymal Stem Cells (BMSCs) Restore Functional Endometrium in the Rat Model for Severe Asherman Syndrome

et al. 2019

View full text Add to dashboard Cite

Objective: To investigate the feasibility to restore functional endometrium using bone marrow mesenchymal stem cells (BMSCs) in the Sprague Dawley (SD["SD" has been defined as both "Sprague Dawley" and "standard deviation." Please clarify which one is to be followed.]) rat model for Asherman syndrome (AS). Design: Basic research on treatment of AS utilizing an optimized rat model. Setting: University research laboratories. Animal(s): Sprague Dawley rat model in which AS was induced in accordance to an optimized protocol. Intervention(s): Bone marrow mesenchymal stem cells were harvested from the rat's bone marrow and labeled with green fluorescent protein (GFP) in the second passage of BMSCs. The fifth passage of GFP-labeled BMSCs was injected systemically through the tail vein in the optimized AS rat model. Main Outcome Measure(s): We examined the reproliferation of the endometrial lining and the expression of markers for endometrium and endometrial receptivity. The localization of engrafted GFPlabeled BMSCs was determined by a laser scanning confocal microscope and a fluorescence microscope. The number of pregnant rats and implanted embryos in each uterus was recorded to evaluate the function of endometrium. Result(s): We had demonstrated that in the in vivo experiments on our rat model for AS, the group which received BMSC injection had significantly improved reproductive outcomes-70% of these rats conceived, whereas none of the rats in the control group got pregnant (P < .01, w 2 test). The mean number of embryos undergoing implantation was 14 + 1.24 in the sham group and 7 + 5.70 in the BMSC group (Levene test, P ¼ .001). There was no significant difference between the groups from the time of coitus to conception. To further determine how BMSC injection could have resulted in the improved reproductive outcomes in rats with AS, we employed immunohistochemical techniques to examine the endometrium of these treated rats. On hematoxylin-eosin staining, we noted the reproliferation of all layers of the endometrium and with Masson staining, we noted significant reduction in fibrosis in the damaged endometrium of rats treated with BMSCs. Counterstaining for GFP and cytokeratin-positive cells was noted in the endometrial lining of treated rats, which might suggest the action of BMSCs in regenerating the damaged endometrial lining. The expression of the endometrial receptivity marker, Leukemia inhibitory factor (LIF), in this regenerated endometrial lining could have resulted in the improved reproductive outcomes observed in the AS rat model treated with BMSCs. Conclusion: Bone marrow mesenchymal stem cells were likely to play an important role in the reconstruction of the injured endometrium and improvement of reproductive outcomes in the optimized AS rat model.

show abstract

Section: Discussionmentioning

confidence: 99%

Bone Marrow Mesenchymal Stem Cells (BMSCs) Restore Functional Endometrium in the Rat Model for Severe Asherman Syndrome

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Here, we conclude four typical articles among them to illustrate the stem cells application for animal models. According to Sevtap and Beril [25], they have designed the experiment to evaluate the effects of stem cells to induce endometrial proliferation and angi-ogenesis on Asherman's Syndrome. This research resulted that the amount of fibrosis, vascularisation, inflammation and immune histochemical staining with vascular endothelial growth factor (VEGF), proliferating cell nuclear antigen (PCNA) and Ki-67 were evaluated in the uterine tissues.…”

Section: Animal Experiments Resultsmentioning

confidence: 99%

Intrauterine Adhesions (IUAs) or Asherman’s Syndrome (AS) and the Stem Cells Treatment: A Systemic Review and Meta-Analysis

Zhang¹,

Mao²,

Zhao³

et al. 2021

JBM

View full text Add to dashboard Cite

Background: Intrauterine Adhesions (IUAs) or Asherman's Syndrome (AS) usually contains symptoms such as decreased menstrual flow or even amenorrhea, chronic pelvic pain, recurrent abortion and infertility. The current treatment of IUAs includes hysteroscopic adhesiolysis, oral hormone and biological barriers, but each of them has limitation. Stem cell therapy may be an expanding field seeking for therapy in IUAs. Objective: We will discuss current advances in stem cell therapy as a treatment for endometrial pathophysiology. Materials and Methods: We search on PubMed, Embase and Cochrane library and select several keywords on researches, then review the cell biology theories and animal experiments, finally do meta-analysis in human clinical trials. Results: 77 articles on PubMed, 71 articles on Embase and 17 articles on Cochrane Library, as a result, 37 articles are included under the criteria, which are intrauterine adhesions (IUAs), Asherman's Syndrome (AS), cell therapy, stem cells, bone marrow stem cells, clinical trials, recent 10 years and human or animal experiments. The included criteria: original articles, cohort study, case control study, animal experiments, human clinical trials, high quality, 10 years recent. The excluded articles are case reports, meeting reports, low quality or more than 10 years ago. Conclusion: Stem cell may be a new therapeutic schedule for IUAs in the future clinical treatment, but it is necessary to compare it with traditional therapy such as oral hormone, also the development of random clinical tests should proceed. For clinical treatment on IUAs, stem cells could be a new choice.

show abstract

“…59 The study of Zhao et al 60 In experimental rat model, the combination of ADSCs and estrogen treatment induced endometrial tissue regeneration. 63…”

Section: Bone Marrow-derived Stem Cellsmentioning

confidence: 99%

“…In experimental rat model, the combination of ADSCs and estrogen treatment induced endometrial tissue regeneration 63 . Shao et al 64 convince that transplantation of ADSCs improves the endometrial injury repair through differentiation ability of ADSCs to endometrial cells.…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cells for restoring endometrial function: An infertility perspective

Rungsiwiwut

Virutamasen

Pruksananonda

2020

Reprod Medicine & Biology

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) can be practically isolated from body tissues such as menstrual blood, 1 adipose tissue, 2 amniotic fluid, 3 and endometrium. 4 Based on their localization in different tissues, the researchers believe that MSCs might be involved in regulation of cells or tissue repair. 5 The characteristics of MSCs derived from different source of tissues can be slightly different. For instance, MSCs derived from bone marrow, umbilical cord blood, adipose tissue, and placenta exhibit differences in immunophenotype, proliferation differentiation ability, and molecular signature. 6 Interestingly, osteogenic differentiation of Mesenchymal stem cells

show abstract

Effect of stem cell application on Asherman Syndrome, an experimental rat model

Cited by 10 publications

References 28 publications

Bone Marrow Mesenchymal Stem Cells (BMSCs) Restore Functional Endometrium in the Rat Model for Severe Asherman Syndrome

Bone Marrow Mesenchymal Stem Cells (BMSCs) Restore Functional Endometrium in the Rat Model for Severe Asherman Syndrome

Intrauterine Adhesions (IUAs) or Asherman’s Syndrome (AS) and the Stem Cells Treatment: A Systemic Review and Meta-Analysis

Mesenchymal stem cells for restoring endometrial function: An infertility perspective

Contact Info

Product

Resources

About